Copenhagen-based Zealand Pharma, the biotech working on a slate of obesity drug candidates, is planting a new research hub in Boston to crank up its metabolic health pipeline. The company says the site will grow its U.S. footprint and is expected to bring on roughly 50 to 100 researchers and technical staff, pairing its peptide expertise with advanced automation and computational drug discovery tools.
Zealand confirms Boston research hub
As reported by Bloomberg, CEO Adam Steensberg told the outlet the firm plans to hire between 50 and 100 people at the new lab. According to Bloomberg, the buildout is part of a broader push in the U.S. as Zealand looks to move its obesity and metabolic programs faster. The company has not yet shared a street address for the Boston facility.
Lab focus: peptides, AI and automation
Zealand's strategy materials describe the Boston site as a hub for "AI-driven drug discovery" and "advanced automation," intended to connect the company’s more than 25 years of peptide R&D with computational methods to speed the journey from idea to clinic, according to Zealand Pharma. The company’s Metabolic Frontier 2030 plan outlines targets for multiple product launches and a strengthened discovery engine that the new U.S. hub is meant to support. Zealand says the Boston move is designed to broaden its molecule-creation toolbox while opening up deeper collaboration opportunities in the U.S.
Why it matters in the obesity drug race
The Boston hub follows Zealand's global collaboration and licensing deal with Roche in March 2025 to co-develop petrelintide, an amylin-based obesity candidate, a partnership that could be worth up to $5.3 billion, according to Roche. That agreement, along with intense competition from major GLP-1 and combo therapy developers, has put a premium on speed and local access to U.S. research talent for smaller biotechs. For Zealand, a Boston lab could tighten its internal discovery timelines and help move combo programs more quickly into late-stage trials.
Local impact and what to watch
Zealand says jobs at the Boston site will likely include computational biologists, medicinal chemists and lab automation engineers, and the company expects to start posting openings as the site ramps up. The firm reiterated its Boston plans in its full-year 2025 results and related investor materials, flagging a catalyst-heavy 2026 and the research hub as a key priority, according to BioSpace. For the region, the pick-up would add one more datapoint that Boston remains a go-to destination for companies trying to fuse drug discovery with AI and automation, along with a modest crop of mid-level lab jobs in the near term.
